Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Cesca

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
The Lamp|February 20, 1999
Mary CescaM Cesca
British Journal of Cancer|June 21, 2012
Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft modelsP Oliva, A Decio, V Castiglioni, et al.
Molecular Biotechnology|July 17, 2014
Recombinant DNA technology for melanoma immunotherapy: anti-Id DNA vaccines targeting high molecular weight melanoma-associated antigenA Barucca, M Capitani, M Cesca, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
The Lamp|February 20, 1999
Mary CescaM Cesca
British Journal of Cancer|June 21, 2012
Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft modelsP Oliva, A Decio, V Castiglioni, et al.
Molecular Biotechnology|July 17, 2014
Recombinant DNA technology for melanoma immunotherapy: anti-Id DNA vaccines targeting high molecular weight melanoma-associated antigenA Barucca, M Capitani, M Cesca, et al.
Pageof 1